Resistance to androgen-pathway drugs in prostate cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Expression of AR-V7 and ARvClinical cancer research : an official journal of the American Association for Cancer Research · 2019
   Trial
2. Detection of Genome-Wide IGF-1R Recruitment to Enhancer and Promoter Regions of Chromatin in Clinical Prostate Cancers.Cancer medicine · 2025
   Article
3. FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells.International journal of oncology · 2024
   Article
4. Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.International journal of molecular sciences · 2022
   Review
5. Circulating tumor cell profiling for precision oncology.Molecular oncology · 2021
   Review
6. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.Cancer research · 2020
   Article
7. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.Cancers · 2019
   Article
8. The influence of BRCA2 mutation on localized prostate cancer.Nature reviews. Urology · 2019
   Review
9. Research status and progress of the RNA or protein biomarkers for prostate cancer.OncoTargets and therapy · 2019
   Review
10. Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens.Neoplasia (New York, N.Y.) · 2017
    Article
11. Drug discovery in advanced prostate cancer: translating biology into therapy.Nature reviews. Drug discovery · 2016
    Review
12. Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.ACS medicinal chemistry letters · 2016
    Article
13. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.Oncotarget · 2015
    Article
14. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.Expert review of anticancer therapy · 2015
    Review
15. Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer.Journal of circulating biomarkers
    Article

Corrections and comments

• Comment on
  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.2014
• Comment on
  Resistance to androgen-pathway drugs in prostate cancer.2014
• Comment on
  Resistance to androgen-pathway drugs in prostate cancer.2014
• Comment on
  Resistance to androgen-pathway drugs in prostate cancer.2014

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as